1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Wall Street is feeling pretty good about 's (NYSE: ABBV) performance in 2024 so far.
Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, which implies a gain of more than 20% from recent prices.
The positive rating is more than a little surprising because AbbVie's lead drug, Humira, lost its market exclusivity in the U.S. last year.
Source Fool.com